# Cizzle Biotechnology repotrs interim results and key partnerships for lung cancer detection

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-repotrs-interim-results-and-key-partnerships-for-lung-cancer-detection/4121172503
- Published: 2024-09-30T07:47:58+01:00
- Author: Amilia Stone

**Cizzle Biotechnology Holdings PLC **(LON:CIZ), the UK based healthcare diagnostics
developer, has announced its unaudited interim results for the six months ended 
30 June 2024.

**Highlights**

·      **March 2024 Fundraising**: The Company successfully raised approximately
£0.62 million through an equity placing. These funds will be used by the Group to
finalise its first commercial test for detecting CIZ1B, to strengthen its intellectual
property, advance its research with the University of York, and support general 
corporate activities.

·      **North America Partnership**: On 2 April 2024, the Group entered into a 
Strategic Licencing and Partnership Memorandum of Understanding for North America
with Cizzle Bio Inc. (“BIO”). Its proprietary CIZ1B biomarker test has subsequently
been selected for a major study at a leading US cancer centre. Cizzle received an
up-front payment of US$100,000 as a non-refundable fee to grant BIO an exclusive
negotiating period from the signing of a memorandum of understanding on 1 April 
2024 (“MoU”).

·      **Research Agreement Extension**: The Group’s research agreement with the
University of York was extended until July 2025.

·      **Financial results**: Loss for the period of £1,411,000 (H1 2023: Loss £
457,000), includes a £1,081,000 (H1 2023: £Nil) fair value loss on a financial asset.
This being a non-cash item, the Group’s net cash used in operating activities (which
excludes proceeds from the issue of ordinary shares) was £238,000 (H1 2023: £327,000).

**Post Period Highlights**

·      **Partnership with BBI Solutions**: In July 2024 the Group announced a strategic
agreement with BBI Solutions, the world’s largest independent producer of immunodiagnostic
reagents, for the supply of monoclonal antibodies. This partnership is a significant
step toward commercialising Cizzle’s cost-effective biomarker test for early-stage
lung cancer detection.

·      **Update on Strategic Licensing Partnership in North America**: On 25 July
2024, Cizzle agreed a 60-day extension with BIO for the completion of the binding
legal agreement as envisaged under the MoU, to enable BIO to complete on additional
strategic investment.

·      **Moffitt Cancer Center Collaboration**: On 9 September 2024, the Group was
selected by Moffitt Cancer Center (“Moffitt”), Florida’s leading cancer hospital,
to test patients with suspicious lung nodules in a clinical evaluation using the
Group’s proprietary CIZ1B biomarker assay. This will be the first time that suspected
lung cancer patients will be tested for the CIZ1B Biomarker as part of a major clinical
evaluation.

> **Commenting Allan Syms, Chairman of Cizzle Biotechnology, said:**
> _“Throughout 2024, the Group has made significant progress in developing its blood
> test to help in the early detection of lung cancer through (i) the manufacturing
> of its core antibodies with BBI Solutions in their_ _ISO 13485-certified facilities__;(
> ii) the industrial collaboration with an industry leading laboratory instrumentation
> partner; and (iii) being selected by the number one cancer centre in Florida to
> conduct a clinical evaluation of our biomarker for their patients presenting with
> suspicious lung nodules. Furthermore, the establishment of a partnership with 
> BIO has now moved the business into the commercial phase of bringing our non-invasive,
> cost effective CIZ1B biomarker lung cancer blood test to market. Not only does
> this mark the achievement of our planned major milestones targeting full product
> launch in April 2025, but also makes our goal of helping detect lung cancer early
> and thereby proving a valuable new means for early intervention and ultimately
> helping save lives. The partnership with BIO is expected to be completed shortly
> giving us the potential for a significant guaranteed royalty deal in North America.”_

**Executive Chairman’s Statement**

_Operational and strategic overview_

Cizzle has focussed on the systematic development and commercialisation of novel
and proprietary clinical diagnostic tests for the early detection of cancer particularly
where there is an unmet clinical need. It is widely considered that to beat cancer,
 early detection and diagnosis is arguably the single most important and impactful
objective we can have. Patients diagnosed early have the best chance of curative
treatment and long-term survival reducing patient stress and improving healthcare
economic performance.

The Group’s platform technology is based on the ability to detect a stable plasma
biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell 
nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly
correlated with early-stage lung cancer. Since the Group’s admission to the London
Stock Exchange in 2021, it has invested in the development of its technology to 
now enable its full commercialisation through a global licensing and partnership
strategy.

With the commercial manufacture of CIZ1B monoclonal antibodies underway, optimisation
of the laboratory platform for the test, collaboration with a major US cancer hospital
and entering shortly into a guaranteed royalty bearing partnership in the USA, the
Group anticipates its proprietary technology will be available for sale in April
2025.

_Research and Development Progress_

Based on the original published research by Professor Coverley and her team at the
University of York, it has been shown that CIZ1B can be measured with high sensitivity
that should allow for non-intrusive, cost effective testing in a high-throughput,
hospital-friendly format and in the future a rapid point of care test for use in
doctors’ offices and pharmacies. During the period, Cizzle continued to support 
its research agreement and collaboration with the University of York which has been
extended to July 2025, and to work with external expert partners and suppliers to
develop and supply of proprietary key monoclonal antibodies and other detector proteins
for its assay platform.

Following the successful generation of new proprietary monoclonal antibodies which
are the central component of the tests to detect the presence of the CIZ1B biomarker,
the Company announced on 18 July 2024 that it had ordered its first batch of antibodies
from BBI Solutions (“BBI”), the world’s largest independent producer of immunodiagnostic
reagents. The initial order is being manufactured at BBI’s ISO 13485-certified facilities
and are expected to support up to 5,000 assays, including the Moffat Cancer Centre
programme, marking a significant inflection point for the Company as it moves from
research and development into commercial manufacture and commencement of the use
of Cizzle’s technology for testing patients in cancer clinics.

_Licensing Strategy and Commercial Progress_

The Company operates a global licensing and partnership strategy because the directors
believe this is the fastest and most cost-effective means to bring its technology
to market. For product solutions, this aims to leverage partners expertise and pre-
existing high throughput platforms to accelerate deployment and installation of 
laboratory testing. Expansion into different geographies aims to maximise speed 
and scale of market entry through specialist licensing partners that provide expert
clinical and commercial teams based in territory that fund all clinical and commercial
activities thereby preserving shareholder funds to focus on next generation products
such as point of care tests and the detection of a wider range of cancers. Wherever
possible we seek up-front fees, guaranteed royalty income and other benefits where
appropriate.

On 19 Sep 2023 the Company announced it had successfully completed an evaluation
programme aimed at assessing the feasibility of using the Simple Western platform
from ProteinSimple for high throughput detection of the CIZ1B cancer biomarker. 
ProteinSimple is part of Bio-Techne Corporation, a NASDAQ Tech listed company. The
Company has continued to optimise that platform to make it suitable for use in laboratories
accredited by the College of American Pathology Pathologists (CAP) with Clinical
Laboratory Improvement Amendments (CLIA) certification.

With commercial antibodies in production and continuing the programme with BioTechne,
the Company was pleased to announce on 2 April 2024 that it had signed a Memorandum
of Understanding (“MoU”) with a new business, funded by high-net worth individuals
as an exclusive licensing partner for the USA and Canada. To align the interests
of the two businesses, the US entity was named Cizzle Bio. The Company received 
a non-refundable upfront fee of US$100,000 and following the completion of the binding
legal agreement, an initial up front royalty of US$300,000 is payable to Cizzle.
Thereafter a royalty of 10% will be paid on revenues using the Company’s technology,
guaranteed by sequential minimum US$ 1 million payments on the 15^(th) and 30^(th)
month anniversaries. The Company will also benefit in a 10% equity stake for no 
cash consideration.

BIO expects to register its first US CLIA accredited lab with the FDA (US Food and
Drug Administration) for the CIZ1B Laboratory Developed Test (LDT) shortly after
completing the licensing agreement and then plans to achieve CLIA Certification 
for the LDT test in November 2024, with insurer reimbursement code achievement and
full product launch April 2025.

Since signing the MOU, BIO has been making significant progress in promoting the
CIZ1B biomarker test and building relationships with clinicians and hospitals across
the USA. The extensive network being generated by BIO and following scientific review,
the Group announced on 9 September 2024 that it had been selected by Moffitt, to
test patients with suspicious lung nodules in a clinical evaluation using the Group’s
proprietary CIZ1B biomarker assay. This is a significant development given the project
will be carried out in the real-world setting of a busy comprehensive cancer centre
with a large lung cancer practice and a high volume, well-organized clinical thoracic
research program.

As part of Moffitt’s Phase 2 programme, “Using Biomarkers for Diagnosis, Risk Stratification
of Post-treatment Recurrence and Long Term Survival of Lung Cancer” (“the programme”),
the Company will for the first time be analysing patient blood samples to determine
biomarker accuracy in predicting whether or not a nodule is likely to be cancer.
The programme is a large observational prospective study in patients with suspicious
indeterminant (undiagnosed) lung nodules seen in the Lung Cancer Early Detection(
LEAD) Center Lung Nodule Clinic, led by its Director Dr. Lary Robinson. The study
follows US recommended guidelines and will be using the first batch of the Company’s
new commercial monoclonal antibody, to provide new sensitivity and specificity data
of the CIZ1B biomarker blood test in the diagnosis of early-stage lung cancer in
people with indeterminant lung nodules. The blood sample tests for CIZ1B will be
conducted in Professor Dawn Coverley’s laboratory at the University of York.

Moffitt note that of the low number of lung cancer patients surviving long term,
most are early-stage patients who had surgical resection.  Unfortunately, with current
screening using low dose chest CT scans (“LDCT”), only 17% are found with localized,
potentially curable disease. And although LDCT is an effective tool in high-risk
populations, only 3.9% of eligible people obtain a scan. Developing a high sensitivity(
>90%) and high specificity (>90%) blood-based biomarker would greatly facilitate
the evaluation of the 1.6 million new lung nodules found yearly on CT scans in the
U.S., differentiating malignant from benign nodules. The study also recognises that
a highly sensitive and specific biomarker potentially could be employed for initial
lung cancer screening with just a blood test at the primary care physicians’ office.

BIO expect to announce further clinical evaluations with additional major US cancer
centres and clinics this year, to be conducted in their growing network of CAP and
CLIA laboratories.

Cizzle Biotechnology already has a further licensing deal in China which is being
progressed as the supply of the Company’s commercial antibodies increases. The programme
will commence after the first laboratory in the US has achieved CLIA accreditation.

_Funding_

In April 2024 the Company successfully raised approximately £0.62 million through
an equity placing, as announced on 26 March 2024. The funds will be utilised towards
completing the Company’s first proposed commercial test to detect CIZ1B which will
be used in the US through our partnership with BIO and planned for full release 
in April 2025, to further protect the Company’s Intellectual Property, progress 
the Company’s research with the University of York and for general corporate purposes.
The Company also terminated the £500,000 loan facility agreement with E3 Fund SP
that was entered into in 2022 and had not been drawn down. In May 2024 the Company
received £78,000 in respect of a non-refundable fee to grant Cizzle Bio an exclusivity
period to negotiate a licensing deal to Cizzle Bio throughout the USA and Canada.

_Financial overview_

During the six months ended 30 June 2024, the Company continued its focus on being
a healthcare diagnostics developer.

The financial results for the six months to 30 June 2024 are summarised as follows:

·    Other income and interest receivable: £79,000 (H1: £Nil)

·    Corporate expenses, before exceptional items: £299,000 (H1 2023: £342,000).

·    Non-cash administrative expenses relating to:

o  Share option charge: £120,000 (H1 2023: £115,000)

o  Net fair value loss on financial asset: £1,081,000 (H1 2023: £Nil)

·    Taxation credit: £10,000 (H1 2023: £26,000)

·    Total comprehensive loss of £1,411,000 (H1 2023, Loss £431,000).

·    Loss per share 0.37p, (H1 2023, Loss of 0.12p).

·    Cash balances as at 30 June 2024: £484,000 (30 June 2023: £451,000).

_Responsibility Statement_

Cizzle Biotechnology confirm that to the best of our knowledge: 

·    the interim financial statements have been prepared in accordance with International
Accounting Standards 34, Interim Financial Reporting;

·    give a true and fair view of the assets, liabilities, financial position and
loss of the Company;

·    the Interim report includes a fair review of the information required by DTR
4.2.7R of the Disclosure and Transparency Rules, being an indication of important
events that have occurred during the first six months of the financial year and 
their impact on the set of interim financial statements; and a description of the
principal risks and uncertainties for the remaining six months of the year; and

·    the Interim report includes a fair review of the information required by DTR
4.2.8R of the Disclosure and Transparency Rules, being the information required 
on related party transactions.

The interim report was approved by the Board of Directors and the above responsibility
statement was signed on its behalf by Allan Syms on 29 September 2024.

*https://www.cancerresearchuk.org/funding-for-researchers/research-opportunities-
in-early-detection-and-diagnosis/early-detection-and-diagnosis-roadmap

Share on:
